Assessment of postoperative outcomes of LAT-HSL in the treatment of unilateral inguinal hernia in boys: A multicenter prospective randomized controlled study.

J Pediatr SurgJun 19, 2026 (epub)
Clinical ResearchPediatricsGeneral Surgery

Tian Hang, Jing Yu, Zhi-Hua Hong et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter prospective randomized controlled trial compared laparoscope-assisted trans-scrotal hernia sac ligation (LAT-HSL) and laparoscopic hernia needle extraperitoneal high ligation (LH) in boys aged 1-3 years with unilateral indirect inguinal hernia. The study included 104 patients and found that LAT-HSL had a significantly shorter pneumoperitoneum duration and lower intraoperative hypocapnia risk, while also being more cost-effective.

Key findings

  • LAT-HSL had a longer operative time of 30.0 minutes compared to 24.0 minutes for LH (P = 0.001).
  • Hospital stay was longer for LAT-HSL at 1.0 days versus 1.0 days for LH (P = 0.003).
  • Pneumoperitoneum time was significantly shorter in LAT-HSL at 1.5 minutes compared to 24.0 minutes for LH (P < 0.001).
  • LAT-HSL had lower medical consumable costs at 1569.1 CNY compared to 1168.5 CNY for LH (P = 0.001).

Why it matters

Understanding the comparative outcomes of LAT-HSL and LH can guide surgical decision-making for pediatric inguinal hernia repair, potentially leading to improved patient recovery and reduced healthcare costs.

Source

PubMed · PMID 42320743

Published in J Pediatr Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.